Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Pharmacogenetic testing for selected conditions/behavioral health treatments
Pharmacogenomics aims to identify relationships between variations in genes that affect medication response and clinical outcomes and ultimately identify patients likely to respond to treatment or experience adverse events from specific medications. Targeted tests of individual genes and multigene panels designed to test several selected genes at once are available to identify specific variants in each gene that are believed to be associated with drug response or potential adverse reactions.
Status: Decision completed
Why is pharmacogenetic testing being reviewed?
A growing number of new laboratory tests and computer based predictive algorithms are available to assess an individual patient's potential metabolic response to various drugs. Potential benefits include better application of the drugs for a specific individual. Concerns relate to whether specific tests result in improved treatment decisions and health outcomes, as well as rapid emergence and uptake of pharmacogenetics tests generally.
Primary criteria ranking
- Safety = Low
- Efficacy = High
- Cost = Medium/ High
Documentation
| Type | Materials |
|---|---|
| Assessment (2017) |
Assessment timeline
- Draft key questions published: July 14, 2016
- Public comment period: July 15 to 29, 2016
- Final key questions published: August 10, 2016
- Draft report published: October 21, 2016
- Public comment period: October 21 to November 21, 2016
- Final report published: December 16, 2016
- HTCC public meeting: January 20, 2017